MDGL Earnings Madrigal Pharmaceuticals, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–26 of 26
| Q2 2026 | 2026-06-30 | -5.24 | 2026-07-30 | 10-Q |
| Q1 2026 | 2026-03-31 | -3.25 | 2026-05-06 | 10-Q |
| Q2 2026 | 2025-12-31 | -10.15 | 2026-07-30 | 10-Q |
| Q2 2026 | 2025-09-30 | -8.12 | 2026-07-30 | 10-Q |
| Q2 2026 | 2025-06-30 | -4.10 | 2026-07-30 | 10-Q |
| Q1 2026 | 2025-03-31 | -2.61 | 2026-05-06 | 10-Q |
| Q2 2026 | 2024-12-31 | -17.31 | 2026-07-30 | 10-Q |
| Q3 2025 | 2024-09-30 | -19.31 | 2025-11-04 | 10-Q |
| Q2 2025 | 2024-06-30 | -14.47 | 2025-08-05 | 10-Q |
| Q1 2025 | 2024-03-31 | -7.38 | 2025-05-01 | 10-Q |
| Q2 2026 | 2023-12-31 | -17.33 | 2026-07-30 | 10-Q |
| Q3 2024 | 2023-09-30 | -14.27 | 2024-10-31 | 10-Q |
| Q2 2024 | 2023-06-30 | -8.91 | 2024-08-07 | 10-Q |
| Q1 2024 | 2023-03-31 | -4.23 | 2024-05-07 | 10-Q |
| FY 2024 | 2022-12-31 | -17.23 | 2025-02-26 | 10-K |
| FY 2023 | 2022-09-30 | -4.75 | 2024-02-28 | 10-K |
| FY 2023 | 2022-06-30 | -4.14 | 2024-02-28 | 10-K |
| FY 2023 | 2022-03-31 | -3.36 | 2024-02-28 | 10-K |
| FY 2023 | 2021-12-31 | -14.63 | 2024-02-28 | 10-K |
| FY 2022 | 2021-09-30 | -3.79 | 2023-02-23 | 10-K |
| FY 2022 | 2021-06-30 | -3.72 | 2023-02-23 | 10-K |
| FY 2022 | 2021-03-31 | -3.32 | 2023-02-23 | 10-K |
| FY 2022 | 2020-12-31 | -13.09 | 2023-02-23 | 10-K |
| FY 2011 | 2011-12-31 | -1.00 | 2012-02-22 | 10-K |
| FY 2011 | 2010-12-31 | -0.93 | 2012-02-22 | 10-K |
| FY 2011 | 2009-12-31 | 2.32 | 2012-02-22 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.